Market Place

Market Place

Market Place

Menu

Post Enquiry

Post Enquiry

PharmaCompass

Home

Market Place

Market Place

Search
All
API
FDF
Price
Services
Excipients
Enquiries

    Find

    • Active Pharmaceutical Ingredients Active Pharmaceutical Ingredients
    • Finished Drug Formulations Finished Drug Formulations
    • Price Price
    • Excipients Excipients
    • Services Services
    • Market Place Marketplace

    Market Place

    Market Place

    Post Enquiry

    Post Enquiry
    pipeline-prospector-insert-v1
    X

    Find Novel Drugs for Hepatology (Liver, Pancreatic, Gall Bladder) under Development

    A collaboration with SCORR Marketing

    Loading...

    All Data

    Filters Filter refresh
    ×
    FILTER DATA :
    Country filter
      News Type filter
        Company filter
          Product Type filter
            Deal Size filter
              refresh

              Product Type

              Companies

              HepaRegeniX GmbH

              • Deals

              Virtual Booth Upgrade this company profile, update & customize all content// Ask PharmaCompass, click HERE

              GERMANY Germany

              Post An Enquiry Post An Enquiry

              Virtual Booth Virtual Booth

              Pharma Nanotech & Nanomedicine

              Participation Not Confirmed

              Request a Meeting Now

              Boehringer, Novo-backed German biotech banks €11M in liver regeneration push

              Contact the Supplier

              Lead Product(s): Undisclosed

              Therapeutic Area: Hepatology (Liver, Pancreatic, Gall Bladder)

              Highest Development Status: Undisclosed Product Type: Undisclosed

              Partner/Sponsor/Collaborator: Boehringer Ingelheim Venture Fund

              Deal Size: $12.2 million Upfront Cash: Undisclosed

              Deal Type: Series B Financing January 21, 2020

              Details:

              The proceeds will be used to advance the first MKK4 inhibitor for treatment of acute and chronic liver diseases to the clinics later in 2020.

              Axcella Health

              • Development Update

              Virtual Booth Upgrade this company profile, update & customize all content// Ask PharmaCompass, click HERE

              UNITED STATES United States

              Post An Enquiry Post An Enquiry

              Virtual Booth Virtual Booth

              Pharma Nanotech & Nanomedicine

              Participation Not Confirmed

              Request a Meeting Now

              Axcella Announces Positive Interim Findings from Ongoing Clinical Study of AXA1125/AXA1957 in Subjects with NAFLD and Expected 2020 Mileston...

              Contact the Supplier

              Lead Product(s): AXA1125

              Therapeutic Area: Hepatology (Liver, Pancreatic, Gall Bladder)

              Highest Development Status: Undisclosed Product Type: Small molecule

              Partner/Sponsor/Collaborator: Not Applicable

              Deal Size: Not Applicable Upfront Cash: Not Applicable

              Deal Type: Not Applicable January 08, 2020

              Details:

              Multifactorial liver and systemic biological activity seen for both AXA1125 and AXA1957 in adult subjects with NAFLD at 16 weeks with onset as early as eight weeks.

              PharmaCompass__DigitalAd